Tsai Susan, Sabel Michael S
University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Surg Oncol Clin N Am. 2008 Apr;17(2):391-419, ix-x. doi: 10.1016/j.soc.2007.12.003.
Current treatment of malignant melanoma exemplifies not only the need for translational research but also many of the challenges of moving from bench to bedside. Melanoma remains unique among solid tumors in that its treatment primarily is surgical. Radiation is of limited benefit, and chemotherapy has been disappointing in both the adjuvant and metastatic settings. This leaves clinicians with few options for reducing the chance of recurrence after surgery and for treating unresectable disease. With this in mind, there has been a fervent attempt to identify novel approaches to melanoma therapy and translate them into clinical use.
恶性黑色素瘤的当前治疗不仅体现了转化研究的必要性,也凸显了从实验室到临床应用过程中的诸多挑战。黑色素瘤在实体瘤中依然独具特点,其治疗主要依靠手术。放疗的益处有限,化疗在辅助治疗和转移性疾病治疗方面都不尽人意。这使得临床医生在降低术后复发几率以及治疗无法切除的疾病方面选择寥寥。鉴于此,人们一直在热切尝试寻找黑色素瘤治疗的新方法并将其转化为临床应用。